News
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...
TipRanks on MSN4d
IO Biotech Regains Nasdaq Compliance with Stock PriceIO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s minimum bid price requirement when its stock ...
The latest price target for IO Biotech (NASDAQ:IOBT) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months ...
The pending Nippon Steel deal would be unusual in granting the U.S. government some control over a private company — models ...
The pending Nippon Steel deal would be unusual in granting the U.S. government some control over a private company—models ...
Financial Square Treasury Instruments Fund FST Shares FTIXX 29.42% Financial Square Government Fund FST Shares FGTXX 15.30% ...
Scope Technologies Corp. ("Scope Technologies" or the "Company") today announced the appointment of Ted Carefoot as Chief Executive Officer, succeeding James Young, who will continue supporting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback